Overview A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors Status: Recruiting Trial end date: 2024-03-23 Target enrollment: Participant gender: Summary This is a study of DP303c in patients with HER2-positive advanced solid tumors. Phase: Phase 1 Details Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.